# Orion Oyj > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/orion). ## Overview Orion is a Finnish pharmaceutical company that operates globally, focusing on the development, manufacturing, and marketing of human and animal medicines, as well as active pharmaceutical ingredients. The company is known for its wide range of original and generic medicines, as well as self-care products. Orion's core therapeutic areas include oncology and pain management. The company is listed on Nasdaq Helsinki and has a significant presence in the Nordic region. ## Products & services • Innovative Medicines • Branded Products • Generics and Consumer Health • Animal Health • Fermion (Active Pharmaceutical Ingredients) - **Innovative Medicines** (30%) — Includes Orion's developed and marketed innovative drugs. - **Branded Products** (20%) — Long-marketed branded pharmaceutical products. - **Generics and Consumer Health** (25%) — Generic drugs and consumer health products. - **Animal Health** (15%) — Pharmaceuticals for veterinary use. - **Fermion** (10%) — Manufacture of active pharmaceutical ingredients for Orion and others. - Innovative Medicines - Branded Products - Generics and Consumer Health - Animal Health - Fermion (Active Pharmaceutical Ingredients) ## Customers Orion serves a diverse range of customers including healthcare professionals, hospitals, pharmacies, and veterinary clinics. The company's innovative medicines are primarily targeted at oncologists and specialists in pain management. Branded products and generics are widely used by general practitioners and pharmacists. The animal health segment caters to veterinarians and pet owners. Orion's Fermion division supplies active pharmaceutical ingredients to other pharmaceutical companies. - **Healthcare Professionals** (primary) — Purchase innovative medicines for oncology and pain management. - **Pharmacies and Hospitals** (primary) — Buy branded and generic pharmaceuticals for distribution. - **Veterinary Clinics** (secondary) — Use animal health products for treating pets and livestock. - **Pharmaceutical Companies** (secondary) — Source active pharmaceutical ingredients from Fermion. - Healthcare professionals seeking innovative treatments for oncology and pain. - Pharmacies and hospitals purchasing branded and generic pharmaceuticals. - Veterinary clinics and pet owners using animal health products. - Pharmaceutical companies sourcing active ingredients from Fermion. ## Geography Orion operates globally with a strong presence in the Nordic region, particularly Finland, which contributes significantly to its revenue. The company also has a growing market in Europe, North America, and other parts of the world. Orion's manufacturing facilities are primarily located in Finland, ensuring high-quality production standards. The company's strategic geographic presence allows it to leverage regional market dynamics and regulatory environments effectively. - **Nordics** (60%) — Finland is a key market. - Strong presence in the Nordic region, especially Finland. - Growing markets in Europe and North America. - Manufacturing facilities located in Finland. - Strategic geographic presence aids in leveraging regional market dynamics. ## Strategy Orion's strategic priorities focus on expanding its innovative medicines portfolio, particularly in oncology and pain management. The company aims to enhance its branded products and generics business in Europe and Asia. Orion is investing in data-driven decision-making to optimize its operations and improve efficiency. The company is also committed to maintaining high ethical standards and fostering a supportive work environment for its employees. - **Expand Innovative Medicines** (medium-term) — To drive growth in oncology and pain management. - **Enhance Branded Products** (medium-term) — To strengthen market position in Europe and Asia. - **Data-Driven Operations** (long-term) — To improve decision-making and efficiency. - Expand innovative medicines portfolio in oncology and pain management. - Enhance branded products and generics business in Europe and Asia. - Invest in data-driven decision-making for operational efficiency. - Maintain high ethical standards and supportive work environment. ## Risks Orion faces several business and financial risks, including regulatory changes in the pharmaceutical industry and geopolitical tensions affecting global supply chains. The company is also exposed to operational risks such as production disruptions and quality control issues. Currency fluctuations pose a financial risk due to Orion's international operations. Additionally, competitive pressures in the generics market could impact profitability. - **Regulatory Changes** [high] — Could affect product approvals and market access. - **Geopolitical Tensions** [critical] — May disrupt supply chains and increase costs. - **Currency Fluctuations** [medium] — Impact financial performance due to international operations. - **Competitive Pressures** [high] — Could erode margins in the generics market. - Regulatory changes affecting pharmaceutical industry operations. - Geopolitical tensions impacting global supply chains. - Operational risks like production disruptions and quality control issues. - Currency fluctuations affecting international operations. - Competitive pressures in the generics market impacting profitability. ## Accounting Orion's financial statements are influenced by critical accounting matters such as revenue recognition from customer contracts, which involves judgment in determining performance obligations. The company also deals with currency translation adjustments due to its international operations. Estimates related to research and development costs are significant, as they impact the timing of expense recognition. Orion adheres to IFRS standards, ensuring transparency and comparability in its financial reporting. - **Revenue Recognition** - **Currency Translation** - **R&D Cost Estimates** - Revenue recognition involves judgment in performance obligations. - Currency translation adjustments due to international operations. - Significant estimates related to research and development costs. - Adherence to IFRS standards for transparency and comparability. --- *Last updated: 2026-08-11T04:04:55.123657+00:00*